CURRICULUM VITAE
IOANNIS (JOHN) T. PARISSIS, MD, FESC
PERSONAL DETAILS
Surname: Parissis
Forename: Ioannis (John)
Date of Birth: 4 June 1965
Gender: Male
Nationality: Greek
Address: Navarinou 13, 15122 Maroussi, Athens, Greece
Day Telephone: +30 6944322627
Home Telephone: +30 210 6123720
Email: jparissis@yahoo.com
MEDICAL EDUCATION
1990
Medical Diploma: University of Patras, Greece
Class of Degree: Excellent
1999
PhD, National University of Crete Medical School
DEGREES AND QUALIFICATIONS
Medical Specialty: Cardiology
1998,
Prefecture of East Attica, Directorate of Health and Welfare, Greece
Consultant Cardiologist: 2000-2004, Heart Failure Clinic, Amalia Fleming Hospital, Athens,
Greece
1
Lecturer, Cardiology: 2005-2009, Heart failure Unit, University of Athens, Greece
Assistant Professor, Cardiology: 2010-2013, Heart failure Unit and Second Department of
Cardiology, University of Athens, Greece.
Honorary Consultant, Heart Failure/ Heart Transplant: 1/1/2011-6/6/2011, Royal Brompton
and Herfield NHS Trust Hospitals, London, UK.
CLINICAL AND RESEARCH EXPERIENCE
Member of faculty of Cardiology Department and Heart Failure Unit, Attikon University
General Hospital, Athens, Greece.
Clinical and research interests include:
Clinical cardiology- Heart Failure
- comorbidities (anemia, depression, diabetes, COPD, obesity) in chronic and acute heart
failure,
- new cardiac enhancers and vasodilators in acute heart failure syndromes and advanced heart
failure (levosimendan, etc),
- biomarkers in heart failure
- management of acute and advanced heart failure
Author or co-author in many publications in peer-reviewed international journals (see list of
publications), numerous cardiology book chapters, and over 200 abstracts in important
scientific meetings, including the American Heart Association Scientific Sessions, the
American College of Cardiology Scientific Meetings, the Annual Congress of the European
2
Society of Cardiology (ESC) and the Annual Congress of the Heart Failure Association of the
ESC.
Reviewer in several international journals (see relevant list). Abstract Grader for the: a) ESC
annual main congress, b) Heart Failure Association of ESC annual congress, and c) Acute
Cardiac Care association of ESC annual congress.
Speaker and/or Chairman
in round tables or clinical seminars in a) ESC annual main
congress, b) Heart Failure Association of ESC annual congress, and c) Acute Cardiac Care
association of ESC annual congress.
Active member of many professional organizations: Chairman of the Hellenic Working Group
on Heart Failure (2007-2008); Fellow of the ESC and a member of the ESC Heart Failure and
Acute Cardiac Care Associations.
Participant in clinical trials in heart failure: BEATIFUL, EMPHASIS, HORIZON-HF,
REACH-UP, ATOMIC-HF, BIOSTAT, BACH.
Member of steering committee of ALARM-HF survey that examined the clinical profile and
management of acute heart failure syndromes in Europe, Latin America and Australia.
Co-Principal Investigator of LEVOREP trial that investigates the role of pulsed infusions of
Levosimendan on advanced heart failure.
National coordinator for Greece and member of international steering committee of the ESC
Pilot Registry on acute and chronic heart failure.
Member of ESC Heart Failure Association committee which co-ordinates European national
working groups or societies on heart failure.
Member of Task Force for Curriculum Heart Failure of ESC Heart Failure Association.
3
Reviewer of ESC guidelines for Heart Failure 2012.
Teaching:
1) Responsible for lectures on Heart Failure for undergraduate medical students (5th
grade), Athens University Medical School, Second Department of Cardiology.
Responsible for clinical training of undergraduate medical students (hands on
experience).
2) Member of committee and/or supervisor of many PhDs on Heart Failure of Athens
University Medical School, Second Department of Cardiology.
3) Member of committee and/or supervisor of many post-graduating programs for nurses,
Athens University, Second Department of Cardiology.
Publications in international per-review journals: Citations-Scopus: 2483; h-index: 27
Total Impact Factor : 549,695 ; Mean Impact factor: 4,133
First Author : 46 publications, Second Author : 38, Last Author : 5
Cardiology :
1. Parissis JT, Papadakis J, Kadoglou NP, Varounis C, Psarogiannakopoulos P, RafouliStergiou P, Ikonomidis I, Paraskevaidis I, Dimopoulou I, Zerva A, Dima K, Anastasiou-Nana
M, Filippatos G. Prognostic value of high sensitivity troponin T in patients with acutely
decompensated heart failure and non-detectable conventional troponin T levels. Int J Cardiol.
2013 May 24. doi:pii: S0167-5273(13)00965-0. 10.1016/j.ijcard.2013.05.056. [Epub ahead of
print].
4
2. Parissis JT, Farmakis D, Fountoulaki K, Rigas A, Nikolaou M, Paraskevaidis IA, Bistola
V, Venetsanou K, Ikonomidis I, Anastasiou-Nana M, Kremastinos DT, Filippatos G. Clinical
and neurohormonal correlates and prognostic value of serum prolactin levels in patients with
chronic heart failure. Eur J Heart Fail. 2013 May 2. [Epub ahead of print].
3. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F,
Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P,
Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; on behalf of the Heart Failure
Association of the European Society of Cardiology (HFA). EURObservational Research
Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot
Survey (ESC-HF Pilot). Eur J Heart Fail. 2013 Mar 28. [Epub ahead of print]
4. Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, Paugam-Burtz C,
Cai D, Pohjanjousi P, Laterre PF, Deye N, Poder P, Solal AC, Mebazaa A. Liver function
abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J.
2012 Oct 22. [Epub ahead of print]
5. Rafouli-Stergiou P, Parissis JT, Anastasiou-Nana M. Inotropes for the management of
acute heart failure patients with renal dysfunction. Still an option? Expert Opin Pharmacother.
2012 Dec;13(18):2637-47.
6. Parissis JT, Mantziari L, Kaldoglou N, Ikonomidis I, Nikolaou M, Mebazaa A,
Altenberger J, Delgado J, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F.
Gender-related differences in patients with acute heart failure: Management and predictors of
in-hospital mortality. Int J Cardiol. 2012 Oct 4. doi:pii: S0167-5273(12)01202-8.
7. Kourouklis SP, Vagiakis E, Paraskevaidis IA, Farmakis D, Kostikas K, Parissis JT,
Katsivas A, Kremastinos DT, Anastasiou-Nana M, Filippatos G. Effective sleep apnoea
5
treatment improves cardiac function in patients with chronic heart failure. Int J Cardiol. 2012
Oct 2. doi:pii: S0167-5273(12)01207-7.
8. Pappas C, Ntai K, Parissis JT, Anastasiou-Nana M. Dual anti-platelet therapy in patients
with G6PD deficiency after percutaneous coronary intervention. Int J Cardiol. 2012 Sep 11.
doi:pii: S0167-5273(12)01053-4.
9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V,
Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP,
Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic
P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis
and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of
Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano
C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA,
Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S,
McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A,
Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B,
Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for
Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart
failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart
Failure 2012 of the European Society of Cardiology. Developed in collaboration with the
Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69.
10. Paraskevaidis IA, Iliodromitis EK, Ikonomidis I, Rallidis L, Hamodraka E, Parissis J,
Andoniadis A, Tzortzis S, Anastasiou-Nana M. The effect of acute administration of statins
on coronary microcirculation during the pre-revascularization period in patients with
myocardial infraction. Atherosclerosis. 2012 Jul;223(1):184-9
6
11. Ikonomidis I, Michalakeas CA, Parissis J, Paraskevaidis I, Ntai K, Papadakis I,
Anastasiou-Nana M, Lekakis J. Inflammatory markers in coronary artery disease.
Biofactors.2012 Sep-Oct;38(5):320-8.
12. Fountoulaki K, Parissis J. Hepatocyte Growth Factor as a Prognostic Marker in Heart
Failure: Promise and Challenges. Cardiology. 2012 May 3;121(4):237-239.
13. Ikonomidis I, Tzortzis S, Paraskevaidis I, Triantafyllidi H, Papadopoulos C, Papadakis I,
Trivilou P, Parissis J, Anastasiou-Nana M, Lekakis J. Association of abnormal coronary
microcirculatory function with impaired response of longitudinal left ventricular function
during adenosine stress echocardiography in untreated hypertensive patients. Eur Heart J
Cardiovasc Imaging. 2012 Dec;13(12):1030-40.
14. Paraskevaidis I, Palios J, Parissis J, Filippatos G, Anastasiou-Nana M. Treating
depression in coronary artery disease and chronic heart failure: what's new in using selective
serotonin re-uptake inhibitors? Cardiovasc Hematol Agents Med Chem. 2012 Jun;10(2):10915.
15. Steinacher R, Parissis JT, Strohmer B, Eichinger J, Rottlaender D, Hoppe UC,
Altenberger J. Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD
criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res
Cardiol. 2012 Aug;101(8):637-45.
16. Parissis JT, Rafouli-Stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, Meas
T, Delgado J, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F. Acute heart
failure in patients with diabetes mellitus: clinical characteristics and predictors of in
hospital mortality. Int J Cardiol. 2012 May 17;157(1):108-13.
7
17. Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F,
Peacock WF, Mebazaa A. Impact of diuretic dosing on mortality in acute heart failure using a
p r o p e n s i t y- m a t c h e d a n a l ys i s . Eur J Heart Fai l . 2011 Nov; 13(11): 1244 -52.
18. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Dasou P, Parissis J, Nikolaou M,
Markantonis SL, Katsimbri P, Skarantavos G, Andreadou I, Anastasiou-Nana M. Association
of soluble apoptotic markers with impaired left ventricular deformation in patients with
rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. Thromb
Haemost. 2011 Nov;106(5):959-67.
19. Michalakeas CA, Parissis JT, Douzenis A, Nikolaou M, Varounis C, Andreadou I,
Antonellos N, Markantonis-Kiroudis S, Paraskevaidis I, Ikonomidis I, Lykouras E,
Kremastinos D. Effects of sertraline on circulating markers of oxidative stress in depressed
patients with chronic heart failure: a pilot study J Card Fail. 2011 Sep;17(9):748-54
20. Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, Mebazaa A,
Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S,
Algotsson L, Wikström BG, Jörgensen K, Filippatos G, Parissis JT, González
MJ,Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F. Levosimendan:
Molecular mechanisms and clinical implications: consensus of experts on the mechanisms of
action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82-7.
21. Filippatos G, Parissis JT. Heart failure diagnosis and prognosis in the elderly: the proof of
the pudding is in the eating. Eur J Heart Fail. 2011 May;13(5):467-71.
22. Ikonomidis I, Michalakeas CA, Lekakis J, Parissis J, Anastasiou-Nana M. The role of
lipoprotein-associated phospholipase A2 (Lp-PLA₂ ) in cardiovascular disease. Rev Recent
8
Clin Trials. 2011 May;6(2):108-13.
23. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N,
McLean A, Vilas-Boas F, Mebazaa Clinical presentation, management and outcomes in the
Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care
Med.2011 Apr;37(4):619-26.
24. Koniari K, Nikolaou M, Paraskevaidis I, Parissis J. Therapeutic options for the
management of the cardiorenal syndrome. Int J Nephrol. 2010 Dec 15;2011:194-199.
25. Paraskevaidis IA, Ikonomidis I, Parissis J, Papadopoulos C, Stassinos V, Bistola V,
Anastasiou-Nana Dobutamine-induced changes of left atrial two-dimensional deformation
predict clinical and neurohumoral improvement after levosimendan treatment in patients with
acutely decompensated chronic heart failure. Int J Cardiol. 2012 May 17;157(1):31-7.
26. Gogas BD, Parissis JT, Iliodromitis EK, Tsiodras S, Radu M, Paraskevaidis IA,
Theodoropoulos SP, Kremastinos DT, Yacoub MH. Left ventricular assist device vegetation:
"cure" without device explantation. Hellenic J Cardiol. 2010 Nov-Dec;51(6):549-51.
27. Parissis JT, Ikonomidis I, Rafouli-Stergiou P, Mebazaa A, Delgado J, Farmakis D, VilasBoas F, Paraskevaidis I, Anastasiou-Nana M, Follath F. Clinical characteristics and predictors
of in-hospital mortality in acute heart failure with preserved left ventricular ejection fraction.
Am J Cardiol. 2011 Jan;107(1):79-84.
28. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, Delgado JF, Follath F.
Short-term survival by treatment among patients hospitalized with acute heart failure: the
global ALARM-HF registry using propensity scoring methods. Intensive Care Med.
2011Feb;37(2):290-301.
9
29. Parissis JT, Nikolaou M, Mebazaa A, Ikonomidis I, Delgado J, Vilas-Boas F, Paraskevaidis
I, Mc Lean A, Kremastinos D, Follath F. Acute pulmonary oedema: clinical characteristics,
prognostic factors, and in-hospital management. Eur J Heart Fail. 2010 Nov;12(11):1193-202.
30. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F,
Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors
A, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of ESC (HFA).
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur
J Heart Fail. 2010 Oct;12(10):1076-84.
31. Ikonomidis I, Varounis C, Paraskevaidis I, Parissis J, Lekakis J, Anastasiou-Nana M.
Congenital left ventricular aneurysm: a cause of impaired myocardial torsion and peripheral
thrombo-embolic events. Eur J Echocardiogr. 2011 Feb;12(2):E7.
32. Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A.
Inotropes in cardiac patients: update 2011. Curr Opin Crit Care. 2010 Oct;16(5):432-41.
33. Paraskevaidis IA, Tsougos E, Varounis C, Dagres N, Karatzas D, Parissis J, Kremastinos
D. Exercise-induced changes of B-type natriuretic peptide uncover the unknown coronary
artery disease in patients with chest pain and normal left ventricular systolic function. Eur J
Cardiovasc Prev Rehabil. 2011 Feb;18(1):72-8.
34. Karavidas A, Parissis JT, Matzaraki V, Arapi S, Varounis C, Ikonomidis I, Grillias P,
Paraskevaidis I, Pirgakis V, Filippatos G, Kremastinos DT. Functional electrical stimulation is
more effective in severe symptomatic heart failure patients and improves their adherence to
rehabilitation programs. J Card Fail. 2010 Mar;16(3):244-9.
35. Tzortzis S, Ikonomidis I, Lekakis J, Papadopoulos C, Triantafyllidi H, Parissis J, Trivilou
P, Paraskevaidis I, Anastasiou-Nana M, Kremastinos DT.Incremental predictive value of
10
carotid intima-media thickness to arterial stiffness for impaired coronary flow reserve in
untreated hypertensives. Hypertens Res . 2010 Apr;33(4):367 -73.
36. Bistola V, Parissis JT, Paraskevaidis I, Panou F, Nikolaou M, Ikonomidis I, Flessas N,
Filippatos G, Iliodromitis E, Kremastinos DT. Prognostic value of tissue Doppler right
ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic
Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated
cardiomyopathy. Am J Cardiol. 2010 Jan 15;105(2):249-54.
37. Kremastinos DT, Hamodraka E, Parissis J, Tsiapras D, Dima K, Maisel A.Predictive
value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in
beta-thalassemia major. Am Heart J. 2010 Jan;159(1):68-74.
38. Altenberger J, Parissis JT, Ulmer H, Poelzl G; LevoRep Investigators. Rationale and
design of the multicentre randomized trial investigating the efficacy and safety of pulsed
infusions of levosimendan in outpatients with advanced heart failure (LevoRep study).Eur J
Heart Fail. 2010 Feb;12(2):186-92.
39. Farmakis D, Parissis J, Kremastinos DTThe prognostic role of echocardiographic indices
in chronic heart failure: right ventricle revisited. Eur J Heart Fail. 2009 Dec;11(12):1220.
40. Ikonomidis I, Paraskevaidis I, Vamvakou G, Parissis J, Lekakis J. The antioxidant effects
of granulocyte colony-stimulating factor. Heart. 2009 Nov;95(21):1801.
41. Parissis JT, Farmakis D, Nikolaou M, Birmpa D, Bistola V, Paraskevaidis I, Ikonomidis
I, Gaitani S, Venetsanou K, Filippatos G, Kremastinos DT.Plasma B-type natriuretic peptide
and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in
chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart
Fail. 2009 Oct;11(10):967-72.
11
42. Parissis JT, Filippatos G. Levosimendan in viral myocarditis: not only an inodilator but
also a cardioprotector? Eur J Clin Invest. 2009 ;39(10):839-40.
43. Paraskevaidis IA, Farmakis D, Papadopoulos C, Ikonomidis I, Parissis J, Rigopoulos A,
Iliodromitis EK, Kremastinos DT. Two-dimensional strain analysis in patients with
hypertrophic cardiomyopathy and normal systolic function: a 12-month follow-up study. Am
Heart J. 2009 ;158(3):444-50.
44. Gogas BD, Parissis JT, Filippatos GS, Iliodromitis EK, Soultanis KC, Kostopanagiotou
GG, Theodoropoulos SP, Kremastinos DT, Yacoub MH. Severe anaemia and subcapital
femur fracture in a patient with Left Ventricular Assist Device Heart Mate II: the cardiologist's
management of this rare patient. Eur J Heart Fail. 2009;11(8):806-8.
45. Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G. Current drugs and
medical treatment algorithms in the management of acute decompensated heart failure. Expert
Opin Investig Drugs. 2009;18(6):695-707.
46. Parissis JT, Kourea K, Andreadou I, Ikonomidis I, Markantonis S, Ioannidis K,
Paraskevaidis I, Iliodromitis E, Filippatos G, Kremastinos DT. Effects of Darbepoetin Alfa on
plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart
failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2009 Apr
15;103(8):1134-8
47. Parissis JT, Nikolaou M, Farmakis D, Paraskevaidis IA, Bistola V, Venetsanou K,
Katsaras D, Filippatos G, Kremastinos DT. Self-assessment of health status is associated with
inflammatory activation and predicts long-term outcomes in chronic heart failure. Eur J Heart
Fail. 2009;11(2):163-9.
48. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A. Levosimendan: from basic
science to clinical practice. Heart Fail Rev. 2009;14(4):265-75
12
49. Parissis JT, Nikolaou M, Birmpa D, Farmakis D, Paraskevaidis I, Bistola V, Katsoulas T,
Filippatos G, Kremastinos DT. Clinical and prognostic value of Duke's Activity Status Index
along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to
ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2009;103(1):73-5.
50. Kirk JD, Parissis JT, Filippatos G. Pharmacologic stabilization and management of acute
heart failure syndromes in the emergency department. Heart Fail Clin. 2009 ;5(1):43-54.
51. Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, Kremastinos
DT. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial
adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating
levels of vascular adhesion molecules. Int J Cardiol. 2008 Nov 10.
52. Farmakis D, Parissis JT, Bistola V, Paraskevaidis IA, Iliodromitis EK, Filippatos G,
Kremastinos DT. Plasma B-type natriuretic peptide reduction predicts long-term response to
levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol. 2008 Oct
28. [Epub ahead of print]
53. Paraskevaidis IA, Bistola V, Ikonomidis I, Parissis JT, Papadopoulos C, Filippatos G,
Kremastinos DT. Usefulness of dobutamine-induced changes of the two-dimensional
longitudinal deformation predict clinical and neurohumoral improvement in men after
levosimendan treatment in acutely decompensated chronic heart failure. Am J Cardiol.
2008;102(9):1225-9
54. Filippatos G, Parissis JT. Vasopressin antagonists for the treatment of acute
decompensated heart failure: when, for whom, for how long, and on what standard therapy? J
Card Fail. 2008;14(8):648-50.
55. Paraskevaidis IA, Panou F, Papadopoulos C, Farmakis D, Parissis J, Ikonomidis I,
Rigopoulos A, Iliodromitis EK, Th Kremastinos D. Evaluation of left atrial longitudinal
13
function in patients with hypertrophic cardiomyopathy: a tissue Doppler imaging and twodimensional strain study. Heart. 2009;95(6):483-9.
56. Farmakis D, Filippatos G, Parissis J, Kremastinos DT, Gheorghiade M. Hyponatremia in
heart failure. Heart Fail Rev. 2009 Jun;14(2):59-63.
57. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT,
Venetsanou KS, Iliodromitis EK, Kremastinos DT. The predictive value of inflammatory and
oxidative markers following the successful cardioversion of persistent lone atrial fibrillation.
Int J Cardiol. 2009 Jul 10;135(3):361-9.
58. Parissis JT, Andreadou I, Bistola V, Paraskevaidis I, Filippatos G, Kremastinos DT.
Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin
Investig Drugs. 2008;17(8):1143-50.
59. Karavidas A, Parissis J, Arapi S, Farmakis D, Korres D, Nikolaou M, Fotiadis J,
Potamitis N, Driva X, Paraskevaidis I, Matsakas E, Filippatos G, Kremastinos DT. Effects of
functional electrical stimulation on quality of life and emotional stress in patients with chronic
heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy: a randomised,
placebo-controlled trial. Eur J Heart Fail. 2008 ;10(7):709-13.
60. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, BubenekTurconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN;
HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects
of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial
in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51(23):2276-85.
61. Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, Kremastinos
DT. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients
with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008;15(3):365-9.
14
62. Blair JE, Macarie C, Ruzyllo W, Bacchieri A, Valentini G, Bianchetti M, Pang PS,
Harinstein ME, Sabbah HN, Filippatos GS, Gheorghiade M; HORIZON-HF investigators.
Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of
istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in
patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther. 2008;15(3):231-40.
63. Karavidas A, Lazaros G, Matsakas E, Farmakis D, Parissis J, Paraskevaidis IA,
Michailidis C, Avramidis D, Zacharoulis A, Arapi S, Kaoukis A, Zacharoulis A. Clinical
value of B-type natriuretic peptide for the assessment of left ventricular filling pressures in
patients with systolic heart failure and inconclusive tissue Doppler indexes. Heart Vessels.
2008;23(3):181-6.
64. Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G,
Kremastinos DT.Effects of darbepoetin alpha on right and left ventricular systolic and
diastolic function in anemic patients with chronic heart failure secondary to ischemic or
idiopathic dilated cardiomyopathy. Am Heart J. 2008 Apr;155(4):751.e1-7
65. Farmakis D, Filippatos G, Lainscak M, Parissis JT, Anker SD, Kremastinos DT.
Anticoagulants, antiplatelets, and statins in heart failure. Cardiol Clin. 2008 Feb;26(1):49-58.
66. De Luca L, Mebazaa A, Filippatos G, Parissis JT, Böhm M, Voors AA, Nieminen M,
Zannad F, Rhodes A, El-Banayosy A, Dickstein K, Gheorghiade M. Overview of emerging
pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008 Feb;10(2):20113. Review.
67. Ikonomidis I, Parissis JT, Paraskevaidis I, Kourea K, Bistola V, Lekakis J, Filippatos G,
Kremastinos DT. Effects of levosimendan on coronary artery flow and cardiac performance in
patients with advanced heart failure. Eur J Heart Fail. 2007;9(12):1172-7.
15
68. Paraskevaidis IA, Kyrzopoulos S, Farmakis D, Parissis J, Tsiapras D, Iliodromitis EK,
Kremastinos DT. Ventricular long-axis contraction as an earlier predictor of outcome in
asymptomatic aortic regurgitation. Am J Cardiol. 2007 ;100(11):1677-82.
69. Kourea K, Parissis JT, Farmakis D, Panou F, Paraskevaidis I, Venetsanou K, Filippatos
G, Kremastinos DT. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, antiinflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients
with chronic heart failure. Atherosclerosis. 2008 Jul;199(1):215-21.
70. Parissis JT, Nikolaou M, Farmakis D, Bistola V, Paraskevaidis IA, Adamopoulos S,
Filippatos G, Kremastinos DT. Clinical and prognostic implications of self-rating depression
scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure.
Heart. 2008;94(5):585-9.
71. Parissis JT, Andreadou I, Markantonis SL, Bistola V, Louka A, Pyriochou A,
Paraskevaidis I, Filippatos G, Iliodromitis EK, Kremastinos DT. Effects of Levosimendan on
circulating markers of oxidative and nitrosative stress in patients with advanced heart failure.
Atherosclerosis. 2007;195(2):e210-5.
72. Parissis J, Fountoulaki K, Paraskevaidis I, Kremastinos DT. Sertraline for the treatment
of depression in coronary artery disease and heart failure. Expert Opin Pharmacother. 2007
Jul;8(10):1529-37.
73. Parissis JT, Papadopoulos C, Nikolaou M, Bistola V, Farmakis D, Paraskevaidis I,
Filippatos G, Kremastinos D. Effects of levosimendan on quality of life and emotional stress
in advanced heart failure patients. Cardiovasc Drugs Ther. 2007;(4):263-8.
74. Parissis JT, Karavidas A, Bistola V, Arapi S, Paraskevaidis IA, Farmakis D, Korres D,
Filippatos G, Matsakas E, Kremastinos DT. Effects of levosimendan on flow-mediated
16
vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure..
Atherosclerosis. 2008 Mar;197(1):278-82.
75. Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers.
Heart Fail Rev. 2007;12(2):149-56.
76. Paraskevaidis IA, Kyrzopoulos S, Tsiapras D, Iliodromitis EK, Parissis J, Farmakis D,
Kremastinos DT. The role of left ventricular long axis contraction in patients with
asymptomatic non-ischemic mitral valve regurgitation and normal systolic function. Int J
Cardiol. 2008 Feb 20;124(1):64-71.
77. Paraskevaidis I, Farmakis D, Parissis JT, Dodouras T, Filippatos G, Tsiapras D,
Kremastinos DT. Carvedilol improves left atrial and left ventricular function and reserve in
dilated cardiomyopathy after 1 year of treatment. J Card Fail. 2007;13(2):108-13
78. Parissis JT, Farmakis D, Bistola V, Adamopoulos S, Kremastinos DT. Levosimendan for
the treatment of acute heart failure syndromes: time to identify subpopulations of responding
patients. Am J Cardiol. 2007 Jan 1;99(1):146-7.
79. Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of
levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with
decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J
Cardiol. 2006 Dec 15;98(12):1641-5.
80. Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, Nikolaou M,
Filippatos G, Kremastinos D. Effects of levosimendan on right ventricular function in patients
with advanced heart failure. Am J Cardiol. 2006 Dec 1;98(11):1489-92.
81. Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F,
Iliodromitis E, Kremastinos DT. Effects of serial levosimendan infusions on left ventricular
17
performance and plasma biomarkers of myocardial injury and neurohormonal and immune
activation in patients with advanced heart failure. Heart. 2006 ;92(12):1768-72.
82. Paraskevaidis I, Parissis JT, Fountoulaki K, Filippatos G, Kremastinos D. Selective
serotonin re-uptake inhibitors for the treatment of depression in coronary artery disease and
chronic heart failure: evidence for pleiotropic effects. Cardiovasc Hematol Agents Med Chem.
2006 Oct;4(4):361-7.
83. Paraskevaidis IA, Vartela V, Tsiapras D, Iliodromitis EK, Parissis J, Farmakis D,
Kremastinos DT. Tissue Doppler imaging analysis at pre-cardioversion time predicts recurrent
atrial fibrillation: a 12-month follow-up study. J Cardiovasc Electrophysiol. 2006;17(9):100510.
84. Karavidas AI, Raisakis KG, Parissis JT, Tsekoura DK, Adamopoulos S, Korres DA,
Farmakis D, Zacharoulis A, Fotiadis I, Matsakas E, Zacharoulis A. Functional electrical
stimulation improves endothelial function and reduces peripheral immune responses in
patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2006 Aug;13(4):592-7.
85. Parissis J, Filippatos G, Adamopoulos S, Li X, Kremastinos DT, Uhal BD.
Hematopoietic colony stimulating factors in cardiovascular and pulmonary remodeling:
promoters or inhibitors? Curr Pharm Des. 2006;12(21):2689-99.
86. Parissis JT, Fountoulaki K, Filippatos G, Adamopoulos S, Paraskevaidis I, Kremastinos
D. Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic
implications. Int J Cardiol. 2007 Mar 20;116(2):153-60.
87. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D,
Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT. Effects of levosimendan versus
dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart
failure. Am J Cardiol. 2006 Jul 1;98(1):102-6.
18
88. Paraskevaidis IA, Tsiapras D, Kyrzopoulos S, Cokkinos P, Iliodromitis EK, Parissis J,
Kremastinos DT. The role of left ventricular long-axis contraction in patients with
asymptomatic aortic regurgitation. J Am Soc Echocardiogr. 2006;19(3):249-54.
89. Parissis JT, Farmakis D, Kremastinos DT. Levosimendan therapy in decompensated
chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
Eur J Heart Fail. 2006 Mar;8(2):215
90. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D.
Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother.
2005 Dec;6(15):2741-51.
91. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I,
Venetsanou K, Lekakis J, Kremastinos DT. Effects of levosimendan on markers of left
ventricular diastolic function and neurohormonal activation in patients with advanced heart
failure. Am J Cardiol. 2005 Aug 1;96(3):423-6.
92. Paraskevaidis IA, Parissis JT, Th Kremastinos D. Anti-inflammatory and anti-apoptotic
effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced
improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc
Hematol Agents. 2005 Jul;3(3):243-7.
93. Parissis JT, Zezas S, Sfiras N, Kastellanos S. An atypical left atrial myxoma causing
intracavitary pressure gradient and typical diastolic transmitral flow of severe mitral stenosis.
Int J Cardiol. 2005 Jun 22;102(1):165-7.
94. Parissis JT, Fountoulaki K, Paraskevaidis I, Kremastinos D. Depression in chronic heart
failure: novel pathophysiological mechanisms and therapeutic approaches. Expert Opin
Investig Drugs. 2005 May;14(5):567-77.
19
95. Karas SM, Parissis JT, Antoniades C, Loulias A. A rare case of large mediastinal germ
cell tumor detected by echocardiography. Int J Cardiol. 2005 May 11;101(1):159-61.
96. Parissis JT, Adamopoulos S, Karatzas D, Paraskevaidis J, Livanis E, Kremastinos D.
Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse
cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated
cardiomyopathy. Eur J Cardiovasc Prev Rehabil. 2005 Apr;12(2):164-8
97. Parissis JT, Farmakis D, Kremastinos DT.Anti-inflammatory effects of levosimendan in
decompensated heart failure: impact on weight loss and anemia. Am J Cardiol. 2005 Apr
1;95(7):923-4.
98. Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E,
Degiannis D, Kremastinos DT. Levosimendan reduces plasma B-type natriuretic peptide and
interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J
Cardiol. 2005 Mar 30;99(3):409-13.
99. Markou N, Antzoulatos N, Haniotou A, Kanakaki M, Parissis J, Damianos A. A case of
drug-induced pneumonitis caused by carvedilol. Respiration. 2004 Nov-Dec;71(6):650-2.
100. Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulou E,
Kortsaris A, Hatseras D. Prolonged activation of tumor necrosis factor (TNF)-alpha and its
soluble receptors in chronic heart failure patients both in the compensated and decompensated
state. Interplay between their levels and metalloproteinase-3. Eur Cytokine Netw. 2004 Jul
Sep;15(3):231-9.
101. Parissis JT, Adamopoulos S, Rigas A, Kostakis G, Karatzas D, Venetsanou K,
Kremastinos DT. Comparison of circulating proinflammatory cytokines and soluble apoptosis
mediators in patients with chronic heart failure with versus without symptoms of depression.
Am J Cardiol. 2004 Nov 15;94(10):1326-8
20
102. Adamopoulos S, Kokkinou S, Parissis JT, Kremastinos DT. New insight into "hearthand" syndromes: a newly discovered chromosomal abnormality in a family with "heart-hand"
syndrome. Int J Cardiol. 2004 Oct;97(1):129-32.
103. Parissis JT, Adamopoulos S, Venetsanou K, Kostakis G, Rigas A, Karas SM,
Kremastinos D. Plasma profiles of circulating granulocyte-macrophage colony-stimulating
factor and soluble cellular adhesion molecules in acute myocardial infarction. Contribution to
post-infarction left ventricular dysfunction. Eur Cytokine Netw. 2004 Apr-Jun;15(2):139-44.
104. Parissis JT, Bistola V, Kostakis GD, Adamopoulos S. Giant unruptured aneurysm of
right valsalva sinus detected by magnetic resonance imaging. Int J Cardiol. 2004
Aug;96(2):299-301
105. Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S,
Iliodromitis E, Kremastinos D. Effects of levosimendan on circulating pro-inflammatory
cytokines and soluble apoptosis mediators in patients with decompensated advanced heart
failure. Am J Cardiol. 2004 May 15;93(10):1309-12.
106. Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED,
Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI. Serum profiles of
matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes.
The effects of short-term atorvastatin administration. Int J Cardiol. 2004 Apr;94(2-3):269-77.
107. Tziakas DN, Chalikias GK, Hatzinikolaou HI, Parissis JT, Papadopoulos ED, Trypsianis
GA, Papadopoulou E, Tentes IK, Karas SM, Hatseras DI. Anti-inflammatory cytokine profile
in acute coronary syndromes: behavior of interleukin-10 in association with serum
metalloproteinases and proinflammatory cytokines. Int J Cardiol. 2003;92(2-3):169-75.
108. Adamopoulos S, Parissis JT, Paraskevaidis I, Karatzas D, Livanis E, Georgiadis M,
Karavolias G, Mitropoulos D, Degiannis D, Kremastinos DT. Effects of growth hormone on
21
circulating cytokine network, and left ventricular contractile performance and geometry in
patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2003 ;24(24):2186-96.
109. Parissis JT, Adamopoulos SN, Venetsanou KF, Karas SM, Kremastinos DT. Elevated
plasma amylase levels in advanced chronic heart failure secondary to ischemic or idiopathic
dilated cardiomyopathy: correlation with circulating interleukin-6 activity. J Interferon
Cytokine Res. 2003 Jun;23(6):329-33.
110. Adamopoulos S, Parissis JT, Kremastinos DT.New aspects for the role of physical
training in the management of patients with chronic heart failure. Int J Cardiol. 2003
Jul;90(1):1-14.
111. Filippatos G, Parissis JT.Estrogen administration in patients with chronic heart failure:
not ready for prime time. Eur J Heart Fail. 2003 Mar;5(2):113-6.
112. Filippatos G, Parissis JT, Adamopoulos S, Kardaras F. Chemokines in cardiovascular
remodeling: clinical and therapeutic implications. Curr Mol Med. 2003 Mar;3(2):139-47.
113. Karas S, Barbetseas J, Lambrou S, Parissis J, Metzikof D, Toutouzas P. Wellfunctioning double-orifice mitral valve in a young adult. J Clin Ultrasound. 2003 MarApr;31(3):170-3.
114. Parissis J, Filippatos G, Nikolaou V, Adamopoulos S. Cytokines and anti-cytokine
therapeutic approaches to chronic heart failure. Eur J Intern Med. 2002 Sep;13(6):356.
115. Adamopoulos S, Parissis JT, Georgiadis M, Karatzas D, Paraskevaidis J, Kroupis C,
Karavolias G, Koniavitou K, Kremastinos DT. Growth hormone administration reduces
circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients
with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J. 2002
Aug;144(2):359-64.
22
116. Adamopoulos S, Parissis JT, Kremastinos DT. Endothelial dysfunction in chronic heart
failure: clinical and therapeutic implications.Eur J Intern Med. 2002 Jun;13(4):233-239.
117. Parissis JT, Venetsanou KF, Kalantzi MV, Mentzikof DD, Karas SM.Serum profiles of
granulocyte-macrophage colony-stimulating factor and C-C chemokines in
hypertensive
patients with or without significant hyperlipidemia. Am J Cardiol. 2000 Mar 15;85(6):777-9
118. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of
peripheral monocyte-related inflammatory markers in patients with arterial hypertension.
Correlations with plasma endothelin-1. Int J Cardiol. 2002 Apr;83(1):13-21.
119. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos
DT. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in
postinfarction left ventricular remodeling. J Interferon Cytokine Res. 2002 Feb;22(2):223-9.
120. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G,
Paraskevaidis J, Koniavitou K, Coats AJ, Kremastinos DT. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic
heart failure. J Am Coll Cardiol. 2002 Feb 20;39(4):653-63.
121. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in
chronic heart failure. Eur J Heart Fail. 2001 Oct;3(5):517-26.
122. Parissis JT, Venetsanou KF, Mentzikof DG, Kalantzi MV, Georgopoulou MV,
Chrisopoulos N, Karas SM. Plasma levels of soluble cellular adhesion molecules in patients
with arterial hypertension. Correlations with plasma endothelin-1. Eur J Intern Med. 2001
Jul;12(4):350-356.
123. Adamopoulos S, Parissis J, Kroupis C, Georgiadis M, Karatzas D, Karavolias G,
Koniavitou K, Coats AJ, Kremastinos DT. Physical training reduces peripheral markers of
inflammation in patients with chronic heart failure. Eur Heart J. 2001 May;22(9):791-7.
23
124. Katritsis D, Korovesis S, Giazitzoglou E, Parissis J, Kalivas P, Webb-Peploe MM,
Ioannidis JP, Haliassos A. C-Reactive protein concentrations and angiographic characteristics
of coronary lesions. Clin Chem. 2001 May;47(5):882-6.
125. Katritsis DG, Ioannidis JP, Korovesis S, Giazitzoglou E, Parissis J, Kalivas P, WebbPeploe MM. Comparison of myocardial fractional flow reserve and intravascular ultrasound
for the assessment of slotted-tube stents. Catheter Cardiovasc Interv. 2001 Mar;52(3):322-6
126. Flouris GA, Arvanitis DA, Parissis JT, et. al. Loss of heterozygosity in DNA mismatch
repair genes in human atherosclerotic plaques. Mol Cell Biol Res Commun. 2000 Jul;4(1):625.
127. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos
DT. Clinical and neurohormonal correlates of circulating granulocyte-macrophage colonystimulating factor in severe heart failure secondary to ischemic or idiopathic dilated
cardiomyopathy. Am J Cardiol. 2000 Sep 15;86(6):707-10, A9-10.
128. Sourvinos G, Parissis J, Sotsiou F, et al.. Detection of microsatellite instability in
sporadic cardiac myxomas. Cardiovasc Res. 1999 Jun;42(3):728-32.
129. Parissis JT, Venetsanou KF, Mentzikof DG, et al . Tumor necrosis factor-alpha serum
activity during treatment of acute decompensation of cachectic and non-cachectic patients
with advanced congestive heart failure. Scand Cardiovasc J. 1999;33(6):344-50.
130. Parissis JT, Mentzikof D, Georgopoulou M, et al. Correlation of interleukin-6 gene
expression to immunologic features in patients with cardiac myxomas. J Interferon Cytokine
Res. 1996 Aug;16(8):589-93.
Oncology :
24
1. Lygidakis NJ, Ziras FA, Kyparidou E, Parissis J, Papadopoulou P, Venetsanou B.
Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma.
Hepatogastroenterology. 1995 Nov-Dec;42(6):1039-52.
2. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E. Combined transarterial
targeting locoregional immunotherapy-chemotherapy for patients
with
unresectable
hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res.
1995 May;15(5):467-72.
3. Lygidakis NJ, Ziras N, Parissis J. Resection versus resection combined with adjuvant preand post-operative chemotherapy--immunotherapy for metastatic colorectal liver cancer. A
new look at an old problem. Hepatogastroenterology. 1995 Apr;42(2):155-61.
Editorial Board:
American Journal of Cardiovascular Disease,
Reviewer:
1. LANCET
2. Circulation
3. Journal of American College of Cardiology
4. European Heart Journal
5. Atherosclerosis
6. European Journal of Heart Failure
7. American Journal of Cardiology
8. American Heart Journal
9. International Journal of Cardiology
10. Journal of Cardiac Failure
11. Heart
12. Clinical Research in Cardiology
13. Intensive Care Medicine
25
14. Heart Failure Reviews
15. Cardiovascular Drugs and Therapy
16. Coronary Artery Disease
17. Clinical Science (London)
18. European Journal of Clinical Investigation
19. Psychosomatic Medicine
20. Brain Behavior and Immunity
21. European Cytokine Network
22. American Journal of Cardiovascular Drugs
23. Expert Opinion on Investigational Drugs
24. Expert Opinion on Pharmacotherapy
25. Herz
26. Anatolian Journal of Cardiology
27. Hellenic Journal of Cardiology
Chapters in international books:
1) “S Adamopoulos, K Fountoulaki, J Parissis: Exercise testing in coronary heart disease”
in Cardiovascular prevention and rehabilitation, Spinger-Verlag London 2007 (Eds J
Perk, H Saner).
2) “Kremastinos D, Parissis J, Filippatos G: Acute Heat Failure Syndromes in BetaThalassemia” in Mebazaa A, Georghiade M, Zannad F, Parillo GA. Eds Acute Heart
Failure, Spinger-Verlag, 2008;297-305.
3) “ Parissis J, Nikolaou M, Tsitlakidis K, Filippatos G, Kremastinos D.
Depression in
chronic heart failure: epidemiology pathophysiology, and diagnostic tools” Chapter VIII
in Leo Sher
(Ed): Psychosocial factors and
cardiovascular disorders: the role of
psychiatric pathology and maladaptive personality features” Nova Science publihers, Inc.
(p111-123).
26
4) “Parissis J, Birmpa D. Acute heart failure: early pharmacological management” Chapter
50 in The European Society of Cardiology Textbook of Intensive and Acute Cardiac Care.
Oxford University Press 2011 (p491-502).
27